2026 Settlement & Supreme Court Updates

Roundup (glyphosate) is the most widely-used herbicide in the world. In the United States, over 3.5 billion pounds of Roundup have been applied by farmers, landscapers, and homeowners since it was first introduced on the market in 1974. Monsanto (now owned by Bayer AG), the manufacturer of Roundup, has long marketed Roundup as a safe and effective method of weed control in residential and commercial settings. However, thousands of individuals have since been diagnosed with Non-Hodgkin Lymphoma (NHL) after regular exposure to Roundup.

At TheLawFirm.com, we are committed to providing the latest updates on ongoing Roundup litigation, including a recent $7.25 billion settlement in state court and a pivotal case currently pending before the U.S. Supreme Court. 

Major 2026 Update: The $7.25 Billion Settlement

In February 2026, Bayer announced a proposed $7.25 billion settlement in King v. Monsanto Company, which is proceeding before Judge Timothy J. Boyer of the Twenty-Second Judicial Circuit Court in Saint Louis, Missouri. This settlement is designed to resolve current and future claims arising out of Non-Hodgkin Lymphoma alleged to have been caused by exposure to Roundup products. 

What you need to know about the 2026 settlement:

• • Preliminary Approval: Judge Boyer gave preliminary approval to the deal on March 4, 2026. 

• Final Approval: Before the settlement can take effect, Judge Boyer must give final approval for the settlement. He is scheduled to hold a Fairness Hearing on July 9, 2026 before giving final approval. 

• • Payout Estimates: Depending on factors like age, severity of illness, and type of exposure, individual awards are estimated to range from $6,000 to over $165,000.
  • The Opt-Out Deadline: If you are a member of the settlement class and wish to pursue an individual lawsuit instead of accepting the settlement, you must formally “opt out” by June 4, 2026. However, the feasibility of potential individual lawsuits will likely be impacted by the ongoing Durnell case pending before the Supreme Court. 
  • Long-Term Funding: The settlement is structured to remain funded for 17 to 21 years to account for future cancer diagnoses. 

• Claim Deadlines: Under the terms of the settlement, those already diagnosed with Non-Hodgkin Lymphoma must file a claim within 180 days of the Court’s final approval of the settlement. Anyone who has not yet been diagnosed with Non-Hodgkin Lymphoma has until 6 years after their diagnosis, though they must submit their claim during the 17-21 year timeline in which the settlement is structured to pay out.

Supreme Court Review: Durnell v. Monsanto

While the settlement moves forward as part of King v. Monsanto in state court, the U.S. Supreme Court is scheduled to hear oral arguments in April 2026 in Durnell v. Monsanto. 

The central question in Durnell is whether the U.S. Environmental Protection Agency’s approval of the Roundup label protects Bayer from state-lawl “failure to warn” claims. A ruling in favor of Bayer could significantly impact the ability of future plaintiffs to file individual claims. Regardless of how the Supreme Court rules in Durnell, the 2026 settlement in the King case will remain a viable option for those diagnosed with Non-Hodgkin Lymphoma as a result of Roundup exposure to seek compensation through the settlement fund. 

Who is Eligible to File a Claim?

If you were exposed to Roundup and later developed cancer, you may be eligible for compensation through the settlement or an independent claim.

Qualifying Criteria Generally Include:

• Significant Exposure: You used Roundup for at least 80 hours in an occupational setting (farm, landscape company, turf company, etc.) or used Roundup for at least 16 hours in a residential setting
• Qualifying Diagnosis: A medical diagnosis of Non-Hodgkin Lymphoma (NHL) or one of its subtypes, such as:
  • B-Cell Lymphoma
  • Chronic Lymphocytic Leukemia (CLL)
  • Follicular Lymphoma
• Timing: Your exposure occurred before February 17, 2026.

High-Risk Groups

Those most at risk for Roundup-related cancers include agricultural workers, professional landscapers, garden center employees, and homeowners who performed frequent yard maintenance with glyphosate-based products.

Why is Roundup Still Being Sold?

As of 2026, Roundup is still sold throughout the United States. For some (but not all) Roundup products, the formulation has changed: 

• Residential Use: Following an initial wave of litigation, Bayer transitioned residential Roundup products to a non-glyphosate formula in 2023. Thus is significant because glyphosate is the ingredient that is associated with causing Non-Hodgkin Lymphoma.
• Commercial Use: Glyphosate-based Roundup continues to be sold for large-scale agricultural and commercial use. This means that unlike Roundup products sold for individual use, Roundup sold for use on farms and in other occupational settings contains the ingredient (glyphosate) that is associated with Non-Hodgkin Lymphoma.
• Regulatory Status: Despite the International Agency for Research on Cancer (IARC) classifying glyphosate as a “probable carcinogen,” the Environmental Protection Agency has maintained that it does not pose a risk to human health when used according to the label. The scientific studies on this issue are mixed, but the EPA’s assessment of glyphosate risks (and its related approval of Roundup labels) represent risks for individual litigation outside the settlement structure in King.